October 8, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology firm that creates, develops and tests HIV/AIDS vaccines, said it has been issued via an exclusive license from Emory University, a US Patent for its "DNA expression vectors and methods of use."

Issued on September 14, 2010, the patent claims cover novel vectors and novel HIV vaccine inserts.

GeoVax has a patent portfolio consisting of over 20 issued and pending patents covering the company's vaccine technology and manufacturing methods. The latest relates to novel plasmid constructs useful for the delivery of DNA vaccines.

Georgia-based GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Goals include developing HIV/AIDS vaccines for global markets, overseeing manufacturing and testing of these vaccines under GMP/GLP conditions, conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the products forward.

=========

Equity research on any public company is available through the Shareholders Research Alliance (go to http://www.investrend.com/synd0004 for more information).  Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html).  Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [biomedphrm] [bsnnssb] [dvcmntnmc] [ftrdnwswnd] [gvrnmnt] [ntrctntcrt] [mlstnsrcgntn] [nvstnggts] [ctvstsvtc]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.